Bicara Therapeutics (BCAX) grants CEO 450,000 stock options

Rhea-AI Filing Summary

Bicara Therapeutics Inc. reported that Chief Executive Officer and director Claire Mazumdar received a grant of stock options. On February 2, 2026, she was awarded options to purchase 450,000 shares of Bicara common stock at an exercise price of $16.76 per share.

The options vest in sixteen equal quarterly installments after February 2, 2026, and each vesting date requires her continued service with the company. Following this grant, she holds 450,000 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazumdar Claire

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.76	02/02/2026		A		450,000		(1)	02/02/2036	Common Stock	450,000	$0	450,000	D

Explanation of Responses:

1. The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bicara Therapeutics (BCAX) report for Claire Mazumdar?

Bicara Therapeutics reported that CEO and director Claire Mazumdar received a grant of 450,000 stock options. The options allow her to purchase Bicara common stock and are documented as a direct holding in this Form 4 insider filing.

What is the exercise price of the new stock options granted by Bicara Therapeutics (BCAX)?

The stock options granted to CEO Claire Mazumdar have an exercise price of $16.76 per share. This is the price at which she can buy Bicara common stock upon exercising the 450,000 options reported in the filing.

How do the Bicara Therapeutics (BCAX) stock options granted to the CEO vest?

The options vest in sixteen equal quarterly installments following February 2, 2026. Each installment requires Claire Mazumdar to continue serving Bicara Therapeutics on the applicable vesting date, spreading vesting over four years from the initial grant date.

How many Bicara Therapeutics (BCAX) derivative securities does the CEO hold after this Form 4?

After the reported transaction, CEO Claire Mazumdar beneficially owns 450,000 stock options directly. All of these options relate to Bicara common stock and are subject to the quarterly vesting schedule described in the Form 4 footnote.

What role does the reporting person hold at Bicara Therapeutics (BCAX) in this Form 4?

The reporting person, Claire Mazumdar, is both a director and the Chief Executive Officer of Bicara Therapeutics Inc. Her positions are explicitly identified in the filing alongside the disclosure of the 450,000 stock option grant.